The Bochum Optimizing Clopidogrel-Aspirin Therapy and MORTality Study (BOCLA-Mort)

Completed

• Conditions: Coronary Artery Disease

• Registration Number: NCT01796691
• Lead Sponsor: Ruhr University of Bochum

Brief Summary

Comparing standard treatment versus optimized antiplatelet therapy and outcomes measures.

Detailed Description

The study is aimed to evaluate if optimized antiplatelet treatment using a test and treat algorithm (with whole blood aggregometry) is able to improve clinical outcome of patients compared to standard treatment without platelet function testing.

Study Timeline

• Study Start: 2009-01
• Status Verified: 2013-02
• Primary Completion: 2013-02
• Study Completion: 2013-02
• Study First Submitted: 2013-02-17
• Study First Submitted QC: 2013-02-21
• Study First Posted: 2013-02-22
• Last Update Submitted: 2013-02-24
• Last Update Posted: 2013-02-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 600

Inclusion Criteria

• coronary stent implantation

Exclusion Criteria

• no consent

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Adverse cardiac events (MACE: mortality,rehospitalisation,myocardial infarction)	Follow up for up to 12 months (retrospective analysis)	MACE-rate

Trial Locations

Locations (1)

Cardiovascular Center, Ruhr-University Bochum; 🇩🇪 Bochum, NRW, Germany